Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348197 | 0.78 | — | — | |
| SCHEMBL28340660 | 0.76 | — | — | |
| Water SCHEMBL19745732 | 0.76 | — | — | |
| Water SCHEMBL19744946 | 0.76 | — | — | |
| SCHEMBL2937188 | 0.68 | ACHE (0.36) | — | |
| Acetic Acid SCHEMBL11657145 | 0.68 | NOX1 (0.33) | — | |
| SCHEMBL5622867 | 0.67 | — | — | |
| SCHEMBL6199756 | 0.66 | — | — | |
| SCHEMBL22639059 | 0.65 | — | — | |
| SCHEMBL27596722 | 0.65 | TRPA1 (0.39) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702043-A1 | INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE | Exelixis, Inc. (US) | 2014-03-05 | — | — | EP | claimed |
| WO-2012149528-A1 | INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE | EXELIXIS, INC. (US) | 2012-11-01 | — | — | WO | claimed |
| EP-1397137-A4 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | claimed |
| EP-1397137-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-17 | — | — | EP | claimed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | claimed |
| US-20230180756-A1 | TRIAZINE AND PYRIMIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-15 | — | — | US | disclosed |
| US-9686985-B2 | Fungicide N-cycloalkyl-N-bicyclicmethylene-carboxamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| US-20160366885-A1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLICMETHYLENE-CARBOXAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH | 2016-12-22 | — | — | US | disclosed |
| US-9468211-B2 | Fungicide N-cycloalkyl-N-bicyclicmethylene-carboxamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-20150327548-A1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLICMETHYLENE-CARBOXAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| EP-2831048-A1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLICMETHYLENE-CARBOXAMIDE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013144086-A1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLICMETHYLENE-CARBOXAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-20040235888-A1 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230180756-A1 | TRIAZINE AND PYRIMIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | TPMT, TYMP, TPI1 | TRPA1 1295/4885 |
| US-20160366885-A1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLICMETHYLENE-CARBOXAMIDE DERIVATIVES | CBR3, CNPY2, CYP51A1 | TRPA1 883/4885 |
| US-20150327548-A1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLICMETHYLENE-CARBOXAMIDE DERIVATIVES | CBR3, CNPY2, CYP51A1 | TRPA1 883/4885 |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | APOL1, PON1, APOB | TRPA1 1752/4885 |
| US-20040235888-A1 | Utilities of amide compounds | APOB, NR1H2, APOL1 | TRPA1 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.